ROSETTA CRC-203: A Blinded, Randomized Phase 2/3 Study of Pumitamig in Combination with Chemotherapy Versus Bevacizumab in Combination with Chemotherapy in Participants with Previously Untreated, Unresectable, or Metastatic Colorectal Cancer. (CA2660003 (ROSETTA CRC-203))

Principal Investigator

Dr Victoria Woodcock

Contact us

Email: latephaseoncology@ouh.nhs.uk

IRAS number

1013201